NOVARTINDNovartis India Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Novartis India Limited is involved in the pharmaceutical business in India. The company offers therapeutic products in the areas of bone and pain products under the Voveran brand; transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands. It also offers neuroscience products under the Tegrital and Exelon brands. Novartis India Limited was incorporated in 1947 and is headquartered in Mumbai, India. Novartis India Limited operates as a subsidiary of Novartis AG.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on NOVARTIND — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 18.6% YoY
- • Profit growth: 16.6% YoY
- • Debt/Equity: 0.00
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • 3-month return: +13.4%
Bull case
- • Revenue growth: 18.6% YoY
- • Profit growth: 16.6% YoY
- • Debt/Equity: 0.00
- • Price vs SMA200: above
Bear case
- • PEG ratio: 2.96
- • Dividend yield: 0.00%
- • MACD: bearish
- • Price vs EMA21: below
Key risks
- • PEG ratio: 2.96
- • Dividend yield: 0.00%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹118.56). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.